Verified: Which Dog Supplement Brands Have Published Peer-Reviewed Clinical Trials?

Evidence Reviews · 17 min read

✓ Our Fact-Checking Team — July 30, 2026

Table of Contents

• The Claim Under Review
• The Distinction That Changes Everything
• Brand-by-Brand Investigation
• The Evidence Master Table
• The Category That Actually Has Product-Level Trials
• Why This Distinction Matters for Your Dog
• How to Verify a “Clinically Studied” Claim Yourself
• Our Verdict and Why
• Frequently Asked Questions
• References

The Claim Under Review

Scan the supplement aisle or the first page of any marketplace search and you’ll encounter a wall of scientific-sounding language: “clinically studied ingredients,” “scientifically formulated,” “research-backed,” “veterinarian developed.” These phrases are carefully chosen. They evoke the rigor of a clinical trial without, in most cases, asserting that the product in your hand has ever been in one.

This isn’t an accident of copywriting. It’s a deliberate strategy that exploits a gap most consumers never think to check: the gap between evidence for an ingredient and evidence for a product. Our broader review of whether pet supplement brands actually test their products found that this gap is the single most common source of misleading claims in the category. This article goes brand by brand.

Before we name names, we need to define the two tiers of evidence precisely, because the entire verdict hinges on the distinction.

The Distinction That Changes Everything

Product-level evidence (the gold standard)

A product-level clinical trial tests the actual finished product — the specific formulation, at the labeled dose, in the delivered format (chew, powder, sachet), given to the target species (dogs), measured against a placebo or control, and published in a peer-reviewed journal. This is the only form of evidence that directly supports a claim about the product you buy. If a trial found that “Product X reduced scratching by 20% versus placebo in 30 dogs over 28 days,” that finding is about Product X.

Ingredient-level evidence (the marketing standby)

An ingredient-level study tests a single component — a strain, a compound, a botanical — often in a different species (humans, mice), often at a different dose, often in a different delivery format. “Strain Y was shown to support gut health in humans” is a real and potentially valuable finding. But it doesn’t establish that a soft chew containing a small amount of strain Y, combined with eleven other ingredients, survives your dog’s stomach and produces the same effect. The bridge from ingredient to product is an extrapolation, and extrapolations can be wrong.

This isn’t a theoretical concern. A 2017 review in the Journal of the American Veterinary Medical Association concluded that “there currently is no definitive evidence^[5] that probiotics are effective for dogs with chronic diarrhea,” and that “a clear role for administration of probiotics to dogs and cats is not evident on the basis of the current literature” (Jugan et al., 2017; PMID: 28207322). That verdict was reached despite abundant ingredient-level research on probiotic strains — precisely because the product-level canine evidence was thin and inconsistent.

With that framework in hand, let us examine the major brands.

Brand-by-Brand Investigation

Purina Pro Plan FortiFlora — VERDICT: TRUE (with an important caveat)

FortiFlora is the exception that proves the rule, and it earns a TRUE rating for the narrow claim “this product has product-level evidence.” Its single strain, Enterococcus faecium SF68, is among the most studied probiotic strains in veterinary medicine, and FortiFlora itself has been evaluated in canine clinical contexts. It’s the product most veterinarians reach for, and that reputation is built on real, product-specific research rather than marketing alone.

The caveat matters, and we would be doing you a disservice to omit it. Even for FortiFlora, the clinical evidence isn’t a clean sweep. The same JAVMA review that recognizes SF68 as well studied also concludes that definitive efficacy for chronic canine diarrhea isn’t established (Jugan et al., 2017; PMID: 28207322). And a 2019 randomized, double-blind, placebo-controlled trial found that a probiotic dosed at roughly 30 billion CFU performed no better than placebo for acute canine diarrhea (Shmalberg et al., 2019; DOI: 10.3389/fvets.2019.00163). So: TRUE that FortiFlora has genuine product-level evidence — but “most studied” isn’t the same as “proven effective for everything it is fed for.”

Nutramax Proviable-DC — VERDICT: MOSTLY TRUE

Proviable-DC is a veterinary staple for gastrointestinal support, a multi-strain capsule widely used in clinics. Nutramax as a company invests in research more than most supplement marketers, and Proviable has been evaluated in veterinary clinical settings. We rate it MOSTLY TRUE: there’s product-relevant clinical evaluation behind it, though the published product-level trial base isn’t as deep or as widely cited as FortiFlora’s SF68 literature. It’s credibly in the “actually studied” tier, just not at the very top of it.

Zesty Paws Probiotic Bites (“Clinically Studied DE111”) — VERDICT: MISLEADING

Zesty Paws headlines its probiotic with Bacillus subtilis DE111 and the phrase “clinically studied.” Here is the precise truth: DE111, the strain, has been studied. The finished Zesty Paws Probiotic Bite — a soft chew combining DE111 with several other strains at a labeled ~3 billion CFU — hasn’t been the subject of a published, peer-reviewed product-level clinical trial that we can identify.

This is the textbook ingredient-versus-product gap. The claim “clinically studied DE111” is literally true at the strain level and functionally misleading at the product level, because a consumer reasonably reads it as “this product has been clinically studied.” It hasn’t. We should also note, for full transparency, that Zesty Paws has faced litigation and independent-lab scrutiny over label accuracy and contaminant issues in other product lines — context that makes rigorous product-level evidence more important, not less, for this brand.

Boops Pets Probiotic — VERDICT: UNVERIFIABLE

Boops Pets markets a 30-billion-CFU, 12-strain probiotic soft chew with quality signals like a NASC seal and references to third-party testing. Those are manufacturing-hygiene signals, not clinical-evidence signals. We couldn’t locate a published, peer-reviewed product-level clinical trial for this specific product. We rate it UNVERIFIABLE rather than MISLEADING because the brand doesn’t lean as heavily on an explicit “clinically studied” claim as some competitors; the evidence simply isn’t in the public record. We examined the related CFU-survival question in depth in our Boops Pets 30 Billion CFU fact check.

PetLab Co. Probiotic Chews (“Clinically Studied Ingredients”) — VERDICT: MISLEADING

PetLab Co. explicitly uses the phrase “clinically studied ingredients,” which is the most honest version of this marketing pattern — it tells you, if you read carefully, that the ingredients are what was studied. The finished multi-strain soft chew hasn’t, to our knowledge, been tested in a published product-level trial. Because the phrasing is technically accurate but predictably read as a product claim, we rate it MISLEADING. Independent reviewers have made the same “no clinical trial data” criticism.

The Evidence Master Table

The table below summarizes our assessment. “Product-Level Trial?” asks the only question that ultimately matters: has the finished product, as sold, been tested in a published peer-reviewed canine trial?

Read the last row carefully. The postbiotic category isn’t a single brand we’re promoting — it’s a formulation approach, and it happens to have accumulated more published, product-level, canine-specific randomized trial evidence than any of the best-selling live-probiotic products above. That’s a verifiable statement, and we document each trial in the next section.

The Category That Actually Has Product-Level Trials

When we apply our own standard — published, peer-reviewed, product-level trials in dogs — the postbiotic category clears it repeatedly. Postbiotics, defined by the ISAPP as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host” (Salminen et al., 2021; DOI: 10.1038/s41575-021-00440-6), have been tested as finished preparations in canine randomized controlled trials:

Trial 1 — Canine oral health postbiotic (halitosis)

A double-blind, placebo-controlled RCT in 24 dogs over 14 days found that a heat-treated postbiotic combining fermentation products of Pediococcus pentosaceus and Bacillus subtilis reduced volatile sulfur compounds (the cause of bad breath) by 27% versus placebo (p=0.004), with twice as many dogs showing perceptibly improved breath and no adverse events (Sordillo et al., 2025; PMID: 40509062; PMC12153626).

Trial 2 — Canine immune health postbiotic (itching / gut-skin axis)

A double-blind, placebo-controlled RCT in 30 dogs over 28 days found that an indole-rich postbiotic reduced scratching by 20% from baseline (p=0.032), reduced perceived itching^[2] by 27% versus placebo (p=0.02), improved skin and coat quality (p=0.01), and increased gut microbiome Shannon diversity by 4.6% (p=0.043), with no adverse events (Sordillo et al., 2025; PMID: 40723482; PMC12291873).

Trial 3 — Postbiotic L. plantarum CECT 9161 (dental plaque)

A placebo-controlled, double-blind 57-day trial in 60 dogs found that a heat-treated Lactiplantibacillus plantarum postbiotic produced a significant 10% reduction in dental plaque^[3] accumulation between Day 29 and Day 57 at the high dose, and modulated the oral microbiome toward oxidative-stress-reduction pathways (Florit-Ruiz et al., 2025; DOI: 10.3390/ani15111615).

Trial 4 — Bifidobacterium animalis BPL1 (gut health, live vs. heat-treated)

A controlled trial in healthy adult dogs compared the live probiotic and heat-treated postbiotic forms of BPL1 and found both were safe and both increased fecal propionate, supporting several aspects of gut health (2024; DOI: 10.1093/jas/skae291). This trial is notable because it directly demonstrates that the inactivated form retains measurable biological activity.

Plus: a 2025 systematic review and meta-analysis

Bonel-Ayuso et al. (2025) screened 157 records, included 69, and analyzed 13 in vivo canine studies in a systematic review and meta-analysis^[4] of postbiotic administration (PMID: 40732081; DOI: 10.3390/microorganisms13071572). In the interest of honesty, we’ll report what it found candidly: the meta-analyses showed no statistically significant differences between postbiotic and control groups for fecal parameters, a signal that the field is still young and the studies heterogeneous. The same review notes that evidence from other species suggests postbiotics “improve the gut microbiota composition, modulate immune and inflammatory responses, reduce oxidative stress, and aid in the treatment of chronic conditions such as atopic dermatitis.”

We include the null finding deliberately. A fact-check that only cites favorable results is marketing, not journalism. The honest summary is this: the postbiotic category has more published product-level canine RCTs than the best-selling live-probiotic brands, the individual trials are positive, and the pooled meta-analytic picture is still maturing. That’s a stronger evidentiary position than “our ingredients were studied once in mice.”

Why This Distinction Matters for Your Dog

Why should you care whether evidence is product-level or ingredient-level? Three practical reasons:

1. Dose and format change everything. A strain that works at 10 billion CFU in a freeze-dried capsule may do nothing at 100 million CFU in a moist soft chew that degraded on a warm shelf. Ingredient studies don’t capture your product’s format.
2. Species matters. A dog’s gastrointestinal physiology, transit time, and resident microbiome differ from a human’s or a mouse’s. Human ingredient data extrapolates to dogs imperfectly at best.
3. Interactions matter. A multi-strain, multi-ingredient chew isn’t the sum of its parts. Strains compete for adhesion sites; ingredients interact. Only a product-level trial tests the actual combination you’re feeding.

This is the same logic we apply in our guide to how to read a clinical trial as a dog owner: the question is never “is there science somewhere?” but “is there science about this exact product, in dogs?”

How to Verify a “Clinically Studied” Claim Yourself

You can pressure-test any “clinically studied” claim in under two minutes:

1. Ask: studied what, exactly? If the brand cites a strain or ingredient study, that’s ingredient-level evidence. Ask whether the finished product has a trial.
2. Search PubMed for the product name AND “dog” or “canine.” A genuine product-level trial will usually surface. If only ingredient reviews appear, you have your answer.
3. Check the species. A trial in humans or mice isn’t a canine trial.
4. Look for “randomized,” “placebo-controlled,” and “peer-reviewed.” An internal “feeding study” or “palatability test” isn’t a clinical trial.
5. Follow the citation. A real claim links to a real paper with a PMID or DOI. Vague “studies show” language with no citation is a red flag.

Our Verdict and Why

We rate the blanket claim that leading dog supplements are “clinically studied” MISLEADING. It isn’t FALSE, because the ingredient-level research behind many of these products is real. But it’s misleading because the phrase systematically leads consumers to infer product-level evidence that, for most brands, doesn’t exist.

The honest hierarchy looks like this: a handful of products (FortiFlora most prominently) have genuine product-level canine evidence; most best-selling soft chews rest on ingredient extrapolation; and the postbiotic category has quietly assembled the deepest product-level canine trial base in the space, even as its meta-analytic picture continues to mature. When a brand says “clinically studied,” you now know the one question that separates substance from spin: studied the ingredient, or studied the product?

The Real Cost of the Evidence Gap

It’s tempting to treat the ingredient-versus-product gap as a harmless technicality — a bit of marketing overreach that doesn’t actually hurt anyone. That framing understates the stakes. When millions of dogs are fed products whose finished formulas have never been tested, the gap has real consequences.

Owners pay a premium for unverified benefit

Supplement marketing prices products as though the clinical evidence existed. A soft chew that rests on a single ingredient study in mice is sold at a “clinical strength” price point, and the consumer has no easy way to know that the evidence never advanced past Level 3. The price signals rigor that the research didn’t deliver. This is the same dynamic we documented with CFU numbers in our “more CFU = better” analysis: a number that feels scientific becomes a pricing lever, disconnected from what has actually been demonstrated.

Dogs receive products of uncertain potency and content

The evidence gap isn’t only about efficacy; it’s also about whether the product contains what it claims. When Weese and Martin (2011) plated out commercial veterinary probiotics, only 27% met their own label claims, and some listed organisms the researchers couldn’t recover at all (PMC3003573). A product that has never been through a product-level trial is also a product that has never been forced to demonstrate, under scrutiny, that its label matches its contents. The two failures — unproven benefit and unverified content — travel together.

The category’s own reviewers are not convinced

This isn’t a skeptical position invented by fact-checkers. The veterinary literature itself is cautious. The 2017 JAVMA review found “no definitive evidence that probiotics are effective for dogs with chronic diarrhea,” and a 2019 randomized trial found a high-count probiotic no better than placebo for acute diarrhea (Shmalberg et al., 2019; DOI: 10.3389/fvets.2019.00163). When the peer-reviewed consensus is this measured, the confident “clinically studied” language on the shelf is doing a lot of unearned work.

What closing the gap would look like

Closing the gap isn’t mysterious. It requires exactly what the postbiotic category has begun to do: run randomized, placebo-controlled trials on the finished product, in dogs, at the labeled dose, and publish the results — including the null results — in peer-reviewed journals. It requires identifying strains to the strain level and demonstrating stability through shelf life. None of this is cheap or fast, which is precisely why so few brands do it. But it’s the difference between a claim and a demonstration, and dog owners deserve to know which one they’re buying.

Until that becomes the norm, the burden falls on consumers to ask the question this article is built around. “Clinically studied” isn’t a verdict. It’s a prompt for a follow-up question: studied the ingredient, or studied the product, and in which species? The answer to that question is the actual evidence base — everything else is packaging.

References

1. Sordillo A, Casella L, Turcotte R, Sheth RU. A Novel Postbiotic Reduces Canine Halitosis. Animals (Basel). 2025;15(11):1596. PMID: 40509062.
2. Sordillo A, Casella L, Turcotte R, Sheth RU. An Indole-Rich Postbiotic Reduces Itching in Dogs. Animals (Basel). 2025;15(14):2019. PMID: 40723482.
3. Florit-Ruiz A, Rago L, Rojas A, et al. Postbiotic Lactiplantibacillus plantarum CECT 9161 Influences the Canine Oral Metagenome and Reduces Plaque Biofilm Formation. Animals (Basel). 2025;15(11):1615. DOI: 10.3390/ani15111615.
4. Bonel-Ayuso DP, et al. Effects of Postbiotic Administration on Canine Health: A Systematic Review and Meta-Analysis. Microorganisms. 2025;13(7):1572. PMID: 40732081.
5. Jugan MC, Rudinsky AJ, Parker VJ, Gilor C. Use of probiotics in small animal veterinary medicine. JAVMA. 2017;250(5):519-528. PMID: 28207322.
6. Effects of supplementation of live and heat-treated Bifidobacterium animalis subsp. lactis BPL1 in dogs. Journal of Animal Science. 2024. DOI: 10.1093/jas/skae291.